{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:08:03Z","timestamp":1789384083984,"version":"build-2803163510"},"reference-count":25,"publisher":"European Respiratory Society (ERS)","issue":"5","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2026,3,30]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Inhaled corticosteroid (ICS)\/long-acting \u03b2\n                      <jats:sub>2<\/jats:sub>\n                      -agonist (LABA) therapy is a mainstay asthma treatment. LITHOS (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">clinicaltrials.gov<\/jats:ext-link>\n                      identifier\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05755906\">NCT05755906<\/jats:ext-link>\n                      ), a randomised phase 3 study, assessed efficacy and safety of low-dose budesonide\/formoterol fumarate dihydrate (BFF)\n                      <jats:italic>via<\/jats:italic>\n                      a metered-dose inhaler (MDI) using Aerosphere co-suspension delivery technology (BFF\n                      <jats:sub>A<\/jats:sub>\n                      )\n                      <jats:italic>versus<\/jats:italic>\n                      low-dose budesonide\n                      <jats:italic>via<\/jats:italic>\n                      MDI using Aerosphere (BD).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Participants (aged 12\u201380\u2005years; N=374) with inadequately controlled asthma (seven-item Asthma Control Questionnaire score \u22651.5) despite low-dose ICS or ICS\/LABA were randomised to 12 weeks of twice-daily BFF 160\/10\u2005\u03bcg (BFF\n                      <jats:sub>A<\/jats:sub>\n                      160) or BD 160\u2005\u03bcg (BD 160). End-points included change from baseline in forced expiratory volume in 1\u2005s (FEV\n                      <jats:sub>1<\/jats:sub>\n                      ) area under the curve from 0\u20133\u2005h (AUC\n                      <jats:sub>0\u20133<\/jats:sub>\n                      ) (primary) and morning pre-dose trough FEV\n                      <jats:sub>1<\/jats:sub>\n                      (key secondary) at week 12, onset of action, severe exacerbation rates and safety\/tolerability.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Least-square mean differences (95% CI) demonstrated that BFF\n                      <jats:sub>A<\/jats:sub>\n                      160 provided superior lung function improvement\n                      <jats:italic>versus<\/jats:italic>\n                      BD 160 at week 12 for change from baseline in FEV\n                      <jats:sub>1<\/jats:sub>\n                      AUC\n                      <jats:sub>0\u20133<\/jats:sub>\n                      (200 (134\u2013267)\u2005mL; p&lt;0.0001) and morning pre-dose FEV\n                      <jats:sub>1<\/jats:sub>\n                      (82 (20\u2013144)\u2005mL; p=0.0096). Severe exacerbation rates were nominally reduced with BFF\n                      <jats:sub>A<\/jats:sub>\n                      160\n                      <jats:italic>versus<\/jats:italic>\n                      BD 160 (rate ratio (95% CI) 0.48 (0.23\u20130.97); unadjusted p=0.0419). No new or unexpected safety findings were observed; on-treatment adverse effects were comparable between treatments (BFF\n                      <jats:sub>A<\/jats:sub>\n                      160, 18.4%; BD 160, 19.5%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      These findings support the use of BFF\n                      <jats:sub>A<\/jats:sub>\n                      160 twice daily with novel Aerosphere technology for the treatment of people aged 12\u201380\u2005years with asthma inadequately controlled by low-dose ICS or ICS\/LABA.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/23120541.01818-2025","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T11:10:22Z","timestamp":1786014622000},"page":"01818-2025","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Budesonide\/formoterol fumarate dihydrate\n                    <i>versus<\/i>\n                    budesonide with a novel suspension technology for uncontrolled asthma: phase 3 LITHOS study"],"prefix":"10.1183","volume":"12","author":[{"given":"Alberto","family":"Papi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8353-2349","authenticated-orcid":false,"given":"Robert A.","family":"Wise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Njira","family":"Lugogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5376-8230","authenticated-orcid":false,"given":"Ruchong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Chami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Armengol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami Z.","family":"Daoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Naucl\u00e9r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Megally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olami","family":"Sobande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehul","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"2026091403451742000_12.5.01818-2025.1","unstructured":"Global Initiative for Asthma . 2025 GINA Report: Global Strategy for Asthma Management and Prevention 2025. Date last accessed: 9 July 2025. https:\/\/ginasthma.org\/2025-gina-strategy-report\/"},{"key":"2026091403451742000_12.5.01818-2025.2","doi-asserted-by":"crossref","first-page":"17534666241254212","DOI":"10.1177\/17534666241254212","article-title":"Relationships between symptoms and lung function in asthma and\/or chronic obstructive pulmonary disease in a real-life setting: the NOVEL observational longiTudinal studY","volume":"18","author":"Papi","year":"2024","journal-title":"Ther Adv Respir Dis"},{"key":"2026091403451742000_12.5.01818-2025.3","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.jaip.2021.10.011","article-title":"A practical guide to implementing SMART in asthma management","volume":"10","author":"Reddel","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026091403451742000_12.5.01818-2025.4","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jaip.2024.01.011","article-title":"The role of ICS-containing rescue therapy versus SABA alone in asthma management today","volume":"12","author":"Krings","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026091403451742000_12.5.01818-2025.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1511190"},{"key":"2026091403451742000_12.5.01818-2025.6","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200666170-00006"},{"key":"2026091403451742000_12.5.01818-2025.7","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2024-222679"},{"key":"2026091403451742000_12.5.01818-2025.8","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1080\/02770903.2018.1455858","article-title":"Burden of asthma among patients adherent to ICS\/LABA: a real-world study","volume":"56","author":"Davis","year":"2019","journal-title":"J Asthma"},{"key":"2026091403451742000_12.5.01818-2025.9","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-017-0710-y"},{"key":"2026091403451742000_12.5.01818-2025.10","unstructured":"AstraZeneca . AstraZeneca announces the completion of the clinical programme to support the transition of Breztri to next-generation propellant with near-zero global warming potential. 2024. Date last accessed: 9 September 2024. www.astrazeneca.com\/media-centre\/press-releases\/2024\/astrazeneca-announces-the-completion-of-the-clinical-programme-to-support-the-transition-of-breztri-to-next-generation-propellant-with-near-zero-global-warming-potential.html"},{"key":"2026091403451742000_12.5.01818-2025.11","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.4155\/fmc.11.133","article-title":"Novel cosuspension metered-dose inhalers for the combination therapy of chronic obstructive pulmonary disease and asthma","volume":"3","author":"Lechuga-Ballesteros","year":"2011","journal-title":"Future Med Chem"},{"key":"2026091403451742000_12.5.01818-2025.12","doi-asserted-by":"crossref","first-page":"15015","DOI":"10.1021\/la302281n","article-title":"Cosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers","volume":"28","author":"Vehring","year":"2012","journal-title":"Langmuir"},{"key":"2026091403451742000_12.5.01818-2025.13","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.2147\/COPD.S510214","article-title":"In silico lung deposition profiles of three single-inhaler triple therapies in patients with COPD using functional respiratory imaging","volume":"20","author":"Singh","year":"2025","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026091403451742000_12.5.01818-2025.14","unstructured":"US Food and Drug Administration . Breztri Aerosphere\u2122 Highlights of Prescribing Information. 2022. Date last accessed: 9 July 2025. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212122s000lbl.pdf"},{"key":"2026091403451742000_12.5.01818-2025.15","unstructured":"European Medicines Agency . Trixeo Aerosphere\u2122 Summary of Product Characteristics. 2020. Date last accessed: 9 July 2025. www.ema.europa.eu\/en\/documents\/product-information\/trixeo-aerosphere-epar-product-information_en.pdf"},{"key":"2026091403451742000_12.5.01818-2025.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.05.011"},{"key":"2026091403451742000_12.5.01818-2025.17","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)60145-7"},{"key":"2026091403451742000_12.5.01818-2025.18","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1081-1206(10)60284-0","article-title":"Patient-reported outcomes in adults with moderate to severe asthma after use of budesonide and formoterol administered via 1 pressurized metered-dose inhaler","volume":"101","author":"Chervinsky","year":"2008","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2026091403451742000_12.5.01818-2025.19","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2147\/JAA.S401445","article-title":"Symptom burden, health status, and productivity in patients with uncontrolled and controlled severe asthma in NOVELTY","volume":"16","author":"Ding","year":"2023","journal-title":"J Asthma Allergy"},{"key":"2026091403451742000_12.5.01818-2025.20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2019-000534"},{"key":"2026091403451742000_12.5.01818-2025.21","doi-asserted-by":"crossref","unstructured":"Jackson DJ , Wise RA , Papi A , et al . Budesonide\/formoterol fumarate dihydrate versus budesonide with a novel suspension technology for uncontrolled asthma: phase 3 VATHOS study. ERJ Open Res 2026; 12: 01817\u20132025. [ 10.1183\/23120541.01817-2025].","DOI":"10.1183\/23120541.01817-2025"},{"key":"2026091403451742000_12.5.01818-2025.22","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01334-2018"},{"key":"2026091403451742000_12.5.01818-2025.23","unstructured":"Electronic Medicines Compendium . Symbicort\u00ae Turbohaler\u00ae 200\/6 Inhalation Powder: Summary of Product Characteristics. 2018. Date last accessed: 1 December 2025. www.medicines.org.uk\/emc\/medicine\/4821"},{"key":"2026091403451742000_12.5.01818-2025.24","unstructured":"AstraZeneca Pharmaceuticals . Symbicort Prescribing Information. 2017. Date last accessed: 1 December 2025. www.azpicentral.com\/symbicort\/symbicort.pdf"},{"key":"2026091403451742000_12.5.01818-2025.25","unstructured":"AstraZeneca Pharmaceuticals LP . Symbicort Summary of Product Characteristics. 2017. Date last accessed: 1 December 2025. www.medicines.org.uk\/emc\/medicine\/32036"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.01818-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:45:28Z","timestamp":1789382728000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.01818-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":25,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9,14]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1183\/23120541.01818-2025"],"URL":"https:\/\/doi.org\/10.1183\/23120541.01818-2025","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]}}}